GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
The opposing effects of ghrelin on hypothalamic and systemic inflammatory processes are modulated by its acylation status and food intake in male rats.
García-Cáceres. Cristina C; Fuente-Martín. Esther E; Díaz. Francisca F; Granado. Miriam M; Argente-Arizón. Pilar P; Frago. Laura M LM; Freire-Regatillo. Alejandra A; Barrios. Vicente V; Argente. Jesús J; Chowen. Julie A JA
Key Findings
- GHRP‑6 and both acylated and non‑acylated ghrelin lowered circulating cytokines while increasing visceral fat in rats.
- In the hypothalamus, ghrelin isoforms and GHRP‑6 raised IGF‑1 production and reduced inflammatory cytokine expression in astrocyte cultures.
- The anti‑inflammatory effects were stronger when animals had unrestricted food access, and no impact was seen on insulin/leptin resistance signaling.
Practical Outcomes
- GHRP‑6 may provide some brain‑focused anti‑inflammatory benefits, but it also promotes visceral fat gain, so its use for longevity or body‑composition goals is a trade‑off. The study used direct brain infusion at doses not comparable to typical peripheral dosing, limiting direct translation to human protocols. Biohackers should weigh potential anti‑inflammatory effects against weight‑gain risks and consider that benefits may depend on overall caloric intake.
Summary
In rats, giving the ghrelin‑mimic GHRP‑6 (and natural ghrelin forms) directly into the brain lowered blood inflammation markers but also made the animals store more belly fat. In the brain, these compounds boosted a protective growth factor (IGF‑1) and reduced inflammatory signals in astrocyte cells, especially when the animals ate freely. However, they didn’t change the pathways that cause insulin or leptin resistance, and the anti‑inflammatory effects varied with food intake.
Abstract
Ghrelin is an endogenous hormone that stimulates appetite and adipose tissue accrual. Both the acylated (AG) and non-acylated (DAG) isoforms of this hormone are also reported to exert anti-inflammatory and protective effects systemically and in the central nervous system. As inflammatory processes have been implicated in obesity-associated secondary complications, we hypothesized that this natural appetite stimulator may protect against negative consequences resulting from excessive food intake. Adult male Wistar rats were treated icv (5 μg/day) with AG, DAG, the ghrelin mimetic GH-releasing peptide (GHRP)-6, AG, and pair-fed with controls (AG-pf) or saline for 14 days. Regardless of food intake AG increased visceral adipose tissue (VAT) and decreased circulating cytokine levels. However, AG reduced cytokine production in VAT only in rats fed ad libitum. Hypothalamic cytokine production was increased in AG-treated rats fed ad libitum and by DAG, but intracellular inflammatory signaling pathways associated with insulin and leptin resistance were unaffected. Gliosis was not observed in response to any treatment as glial markers were either reduced or unaffected. AG, DAG, and GHRP-6 stimulated production of hypothalamic insulin like-growth factor I that is involved in cell protective mechanisms. In hypothalamic astrocyte cell cultures AG decreased tumor necrosis factorα and DAG decreased interleukin-1β mRNA levels, suggesting direct anti-inflammatory effects on astrocytes. Thus, whereas ghrelin stimulates food intake and weight gain, it may also induce mechanisms of cell protection that help to detour or delay systemic inflammatory responses and hypothalamic gliosis due to excess weight gain, as well as its associated pathologies.
Study Information
pubmed
2014
2014-05-21T00:00:00.000Z
10.1210/en.2014-1074
27
80